Achilles Therapeutics Ownership 2024 | Who Owns Achilles Therapeutics Now?
Institutional Ownership
55.08%
Insider Ownership
6.51%
Retail Ownership
38.40%
Institutional Holders
26.00
Achilles Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SYNCONA PORTFOLIO LTD | 27.52% | 10.52% | 11,086,909 | - | - | 9,035,831 | Jun 30, 2024 |
| FCPM III SERVICES B.V. | 5.93% | 0.29% | 2,390,050 | - | - | 1,947,891 | Jun 30, 2024 |
| REDMILE GROUP, LLC | 3.99% | 0.08% | 1,608,089 | - | - | 1,310,593 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 3.72% | 0.09% | 1,500,000 | - | - | 1,222,500 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 3.58% | 0.20% | 1,443,181 | - | - | 1,176,193 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 2.75% | 0.01% | 1,108,767 | -100,008 | -8.27% | 903,645 | Jun 30, 2024 |
| ARTAL GROUP S.A. | 1.88% | 0.02% | 755,375 | - | - | 615,631 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 1.69% | 0.00% | 682,734 | -323,025 | -32.12% | 556,428 | Jun 30, 2024 |
| BML CAPITAL MANAGEMENT, LLC | 1.55% | 0.36% | 625,174 | 625,174 | 100.00% | 509,517 | Jun 30, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.04% | 0.01% | 420,481 | - | - | 342,692 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.62% | 0.00% | 250,825 | -30,104 | -10.72% | 203,000 | Jun 30, 2024 |
| UBS GROUP AG | 0.16% | - | 65,700 | 65,700 | 100.00% | 53,546 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.13% | 0.00% | 51,660 | 36,441 | 239.44% | 42,103 | Jun 30, 2024 |
| VIRTU FINANCIAL LLC | 0.06% | 0.00% | 22,813 | 1,866 | 8.91% | 19,000 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.05% | - | 21,590 | - | - | 17,595 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.05% | - | 21,478 | 9,679 | 82.03% | 17,505 | Jun 30, 2024 |
| BAADER BANK AKTIENGESELLSCHAFT | 0.03% | 0.00% | 12,369 | 12,369 | 100.00% | 8,210 | Jun 30, 2024 |
| HRT FINANCIAL LP | 0.03% | - | 10,942 | -25,976 | -70.36% | 8,000 | Jun 30, 2024 |
| BRAVE ASSET MANAGEMENT INC | 0.02% | 0.00% | 10,000 | - | - | 8,150 | Jun 30, 2024 |
| MORGAN STANLEY | 0.02% | - | 8,931 | -9,270 | -50.93% | 7,279 | Jun 30, 2024 |
Achilles Therapeutics's largest institutional shareholder is SYNCONA PORTFOLIO LTD, holding 27.52% of the company's total share outstanding, currently valued at $9.04M. The top 10 institutional shareholders own together 53.67% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SYNCONA PORTFOLIO LTD | 27.52% | 10.52% | 11,086,909 | - | - | 9,035,831 | Jun 30, 2024 |
| BML CAPITAL MANAGEMENT, LLC | 1.55% | 0.36% | 625,174 | 625,174 | 100.00% | 509,517 | Jun 30, 2024 |
| FCPM III SERVICES B.V. | 5.93% | 0.29% | 2,390,050 | - | - | 1,947,891 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 3.58% | 0.20% | 1,443,181 | - | - | 1,176,193 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 3.72% | 0.09% | 1,500,000 | - | - | 1,222,500 | Jun 30, 2024 |
| REDMILE GROUP, LLC | 3.99% | 0.08% | 1,608,089 | - | - | 1,310,593 | Jun 30, 2024 |
| ARTAL GROUP S.A. | 1.88% | 0.02% | 755,375 | - | - | 615,631 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 2.75% | 0.01% | 1,108,767 | -100,008 | -8.27% | 903,645 | Jun 30, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.04% | 0.01% | 420,481 | - | - | 342,692 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.13% | 0.00% | 51,660 | 36,441 | 239.44% | 42,103 | Jun 30, 2024 |
| BRAVE ASSET MANAGEMENT INC | 0.02% | 0.00% | 10,000 | - | - | 8,150 | Jun 30, 2024 |
| VIRTU FINANCIAL LLC | 0.06% | 0.00% | 22,813 | 1,866 | 8.91% | 19,000 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 1.69% | 0.00% | 682,734 | -323,025 | -32.12% | 556,428 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.62% | 0.00% | 250,825 | -30,104 | -10.72% | 203,000 | Jun 30, 2024 |
| BAADER BANK AKTIENGESELLSCHAFT | 0.03% | 0.00% | 12,369 | 12,369 | 100.00% | 8,210 | Jun 30, 2024 |
| GLOBAL RETIREMENT PARTNERS, LLC | 0.01% | 0.00% | 2,000 | - | - | 1,630 | Jun 30, 2024 |
| HRT FINANCIAL LP | 0.03% | - | 10,942 | -25,976 | -70.36% | 8,000 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.05% | - | 21,478 | 9,679 | 82.03% | 17,505 | Jun 30, 2024 |
| UBS GROUP AG | 0.16% | - | 65,700 | 65,700 | 100.00% | 53,546 | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 0.01% | - | 4,480 | 966 | 27.49% | 3,649 | Jun 30, 2024 |
The largest Achilles Therapeutics shareholder by % of total assets is SYNCONA PORTFOLIO LTD. The company owns 11.09M shares of Achilles Therapeutics (ACHL), representing 10.52% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BML CAPITAL MANAGEMENT, LLC | 1.55% | 0.36% | 625,174 | 625,174 | 100.00% | 509,517 | Jun 30, 2024 |
| UBS GROUP AG | 0.16% | - | 65,700 | 65,700 | 100.00% | 53,546 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.13% | 0.00% | 51,660 | 36,441 | 239.44% | 42,103 | Jun 30, 2024 |
| BAADER BANK AKTIENGESELLSCHAFT | 0.03% | 0.00% | 12,369 | 12,369 | 100.00% | 8,210 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.05% | - | 21,478 | 9,679 | 82.03% | 17,505 | Jun 30, 2024 |
| VIRTU FINANCIAL LLC | 0.06% | 0.00% | 22,813 | 1,866 | 8.91% | 19,000 | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 0.01% | - | 4,480 | 966 | 27.49% | 3,649 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.00% | - | 137 | - | - | 112 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.00% | - | 73 | - | - | 59 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.05% | - | 21,590 | - | - | 17,595 | Jun 30, 2024 |
| GLOBAL RETIREMENT PARTNERS, LLC | 0.01% | 0.00% | 2,000 | - | - | 1,630 | Jun 30, 2024 |
| BRAVE ASSET MANAGEMENT INC | 0.02% | 0.00% | 10,000 | - | - | 8,150 | Jun 30, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.04% | 0.01% | 420,481 | - | - | 342,692 | Jun 30, 2024 |
| ARTAL GROUP S.A. | 1.88% | 0.02% | 755,375 | - | - | 615,631 | Jun 30, 2024 |
| REDMILE GROUP, LLC | 3.99% | 0.08% | 1,608,089 | - | - | 1,310,593 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 3.72% | 0.09% | 1,500,000 | - | - | 1,222,500 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 3.58% | 0.20% | 1,443,181 | - | - | 1,176,193 | Jun 30, 2024 |
| FCPM III SERVICES B.V. | 5.93% | 0.29% | 2,390,050 | - | - | 1,947,891 | Jun 30, 2024 |
| SYNCONA PORTFOLIO LTD | 27.52% | 10.52% | 11,086,909 | - | - | 9,035,831 | Jun 30, 2024 |
| ICA GROUP WEALTH MANAGEMENT, LLC | - | - | - | -400 | -100.00% | - | Jun 30, 2024 |
As of Jun 30 2024, Achilles Therapeutics's largest institutional buyer is BML CAPITAL MANAGEMENT, LLC. The company purchased 625.17K stocks of ACHL, valued at $509.52K.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| STEMPOINT CAPITAL LP | - | - | - | -1,385,750 | -100.00% | - | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 1.69% | 0.00% | 682,734 | -323,025 | -32.12% | 556,428 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 2.75% | 0.01% | 1,108,767 | -100,008 | -8.27% | 903,645 | Jun 30, 2024 |
| FOREFRONT ANALYTICS, LLC | - | - | - | -95,445 | -100.00% | - | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.62% | 0.00% | 250,825 | -30,104 | -10.72% | 203,000 | Jun 30, 2024 |
| HRT FINANCIAL LP | 0.03% | - | 10,942 | -25,976 | -70.36% | 8,000 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -19,117 | -100.00% | - | Jun 30, 2024 |
| VONTOBEL HOLDING LTD. | - | - | - | -19,000 | -100.00% | - | Jun 30, 2024 |
| TWO SIGMA SECURITIES, LLC | - | - | - | -16,312 | -100.00% | - | Jun 30, 2024 |
| RESOURCES INVESTMENT ADVISORS, LLC. | - | - | - | -10,500 | -100.00% | - | Jun 30, 2024 |
| MORGAN STANLEY | 0.02% | - | 8,931 | -9,270 | -50.93% | 7,279 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | - | - | - | -1,092 | -100.00% | - | Jun 30, 2024 |
| ICA GROUP WEALTH MANAGEMENT, LLC | - | - | - | -400 | -100.00% | - | Jun 30, 2024 |
| SYNCONA PORTFOLIO LTD | 27.52% | 10.52% | 11,086,909 | - | - | 9,035,831 | Jun 30, 2024 |
| FCPM III SERVICES B.V. | 5.93% | 0.29% | 2,390,050 | - | - | 1,947,891 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 3.58% | 0.20% | 1,443,181 | - | - | 1,176,193 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 3.72% | 0.09% | 1,500,000 | - | - | 1,222,500 | Jun 30, 2024 |
| REDMILE GROUP, LLC | 3.99% | 0.08% | 1,608,089 | - | - | 1,310,593 | Jun 30, 2024 |
| ARTAL GROUP S.A. | 1.88% | 0.02% | 755,375 | - | - | 615,631 | Jun 30, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.04% | 0.01% | 420,481 | - | - | 342,692 | Jun 30, 2024 |
As of Jun 30 2024, Achilles Therapeutics's biggest institutional seller is STEMPOINT CAPITAL LP. The company sold -1.39M shares of ACHL, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BML CAPITAL MANAGEMENT, LLC | 1.55% | 0.36% | 625,174 | 625,174 | 100.00% | 509,517 | Jun 30, 2024 |
| UBS GROUP AG | 0.16% | - | 65,700 | 65,700 | 100.00% | 53,546 | Jun 30, 2024 |
| BAADER BANK AKTIENGESELLSCHAFT | 0.03% | 0.00% | 12,369 | 12,369 | 100.00% | 8,210 | Jun 30, 2024 |
Achilles Therapeutics's largest new institutional shareholder by number of shares is BML CAPITAL MANAGEMENT, LLC, purchased 625.17K shares, valued at $509.52K, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| STEMPOINT CAPITAL LP | - | - | - | -1,385,750 | -100.00% | - | Jun 30, 2024 |
| FOREFRONT ANALYTICS, LLC | - | - | - | -95,445 | -100.00% | - | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -19,117 | -100.00% | - | Jun 30, 2024 |
| VONTOBEL HOLDING LTD. | - | - | - | -19,000 | -100.00% | - | Jun 30, 2024 |
| TWO SIGMA SECURITIES, LLC | - | - | - | -16,312 | -100.00% | - | Jun 30, 2024 |
| RESOURCES INVESTMENT ADVISORS, LLC. | - | - | - | -10,500 | -100.00% | - | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | - | - | - | -1,092 | -100.00% | - | Jun 30, 2024 |
| ICA GROUP WEALTH MANAGEMENT, LLC | - | - | - | -400 | -100.00% | - | Jun 30, 2024 |
Achilles Therapeutics's largest sold out institutional shareholder by shares sold is STEMPOINT CAPITAL LP, sold -1.39M shares, valued at -, as of undefined.
Achilles Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| Collaborative Investment Series Trust | 0.46% | 71,927 | - | - | Mar 31, 2024 |
| ALLSPRING MASTER TRUST | 0.00% | 214,873 | - | - | Feb 29, 2024 |
| OPTIMUM FUND TRUST | 0.00% | 40,402 | - | - | Mar 28, 2024 |
| LoCorr Investment Trust | 0.00% | 18,782 | - | - | Mar 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 21,590 | - | - | Feb 29, 2024 |
| PACE SELECT ADVISORS TRUST | 0.00% | 25,934 | - | - | Jan 31, 2024 |
| iSHARES TRUST | 0.00% | 238,114 | - | - | Mar 31, 2024 |
| SEI INSTITUTIONAL MANAGED TRUST | 0.00% | 39,027 | - | - | Dec 31, 2023 |
| PROSHARES TRUST | 0.00% | 3,293 | - | - | Feb 29, 2024 |
| EMPOWER FUNDS, INC. | 0.00% | 12,361 | - | - | Mar 31, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 723 | - | - | Jan 31, 2024 |
| Blackstone Alternative Investment Funds | 0.00% | 100 | 100 | - | Mar 31, 2024 |
Achilles Therapeutics's largest mutual fund holder by % of total assets is "Collaborative Investment Series Trust", owning 71.93K shares, compromising 0.46% of its total assets.
Achilles Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 26 | -16.13% |
| 31 Mar, 24 | 31 | 63.16% |
| 31 Dec, 23 | 19 | 11.76% |
| 30 Sep, 23 | 17 | 6.25% |
| 30 Jun, 23 | 16 | - |
| 31 Mar, 23 | 16 | -23.81% |
| 31 Dec, 22 | 21 | -19.23% |
| 30 Sep, 22 | 26 | 13.04% |
| 30 Jun, 22 | 23 | 4.55% |
| 31 Mar, 22 | 22 | -24.14% |
| 31 Dec, 21 | 29 | 45.00% |
| 30 Sep, 21 | 20 | -31.03% |
| 30 Jun, 21 | 29 | - |
| 31 Mar, 21 | 29 | - |
As of 30 Jun 24, 26 institutions are holding Achilles Therapeutics's shares, representing a decrease of -16.13% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 22,188,649 | -5.62% |
| 31 Mar, 24 | 23,510,455 | 7.93% |
| 31 Dec, 23 | 21,782,170 | 10.61% |
| 30 Sep, 23 | 19,692,035 | -0.48% |
| 30 Jun, 23 | 19,786,405 | -2.22% |
| 31 Mar, 23 | 20,235,741 | -6.60% |
| 31 Dec, 22 | 21,665,748 | -20.55% |
| 30 Sep, 22 | 27,269,868 | 0.50% |
| 30 Jun, 22 | 27,135,177 | 2.13% |
| 31 Mar, 22 | 26,568,801 | -3.15% |
| 31 Dec, 21 | 27,433,848 | 55.90% |
| 30 Sep, 21 | 17,597,157 | -6.32% |
| 30 Jun, 21 | 18,784,796 | 11.77% |
| 31 Mar, 21 | 16,807,348 | - |
Achilles Therapeutics (ACHL) has 22.19M shares outstanding as of 30 Jun 24, down -5.62% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 55.08% | 1.61% |
| 31 Mar, 24 | 58.50% | 1.98% |
| 31 Dec, 23 | 54.36% | 2.23% |
| 30 Sep, 23 | 49.35% | 1.99% |
| 30 Jun, 23 | 49.80% | 1.92% |
| 31 Mar, 23 | 50.93% | 1.68% |
| 31 Dec, 22 | 55.11% | 1.15% |
| 30 Sep, 22 | 69.36% | 1.44% |
| 30 Jun, 22 | 69.39% | 1.49% |
| 31 Mar, 22 | 68.31% | 0.75% |
| 31 Dec, 21 | 95.74% | 4.53% |
| 30 Sep, 21 | 45.99% | 1.66% |
| 30 Jun, 21 | 52.64% | 2.37% |
| 31 Mar, 21 | 47.10% | - |
As of 30 Jun 24, Achilles Therapeutics is held by 55.08% institutional shareholders, representing a 1.61% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 8 | -55.56% |
| 31 Mar, 24 | 18 | 125.00% |
| 31 Dec, 23 | 8 | 33.33% |
| 30 Sep, 23 | 6 | 50.00% |
| 30 Jun, 23 | 4 | -33.33% |
| 31 Mar, 23 | 6 | -45.45% |
| 31 Dec, 22 | 11 | -15.38% |
| 30 Sep, 22 | 13 | 44.44% |
| 30 Jun, 22 | 9 | 12.50% |
| 31 Mar, 22 | 8 | -55.56% |
| 31 Dec, 21 | 18 | 200.00% |
| 30 Sep, 21 | 6 | -40.00% |
| 30 Jun, 21 | 10 | -65.52% |
| 31 Mar, 21 | 29 | - |
8 institutional shareholders have increased their position in ACHL stock as of 30 Jun 24 compared to 18 in the previous quarter (a -55.56% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 6 | -25.00% |
| 31 Mar, 24 | 8 | 100.00% |
| 31 Dec, 23 | 4 | - |
| 30 Sep, 23 | 4 | -33.33% |
| 30 Jun, 23 | 6 | 200.00% |
| 31 Mar, 23 | 2 | -60.00% |
| 31 Dec, 22 | 5 | -16.67% |
| 30 Sep, 22 | 6 | - |
| 30 Jun, 22 | 6 | -14.29% |
| 31 Mar, 22 | 7 | 250.00% |
| 31 Dec, 21 | 2 | -50.00% |
| 30 Sep, 21 | 4 | -69.23% |
| 30 Jun, 21 | 13 | - |
| 31 Mar, 21 | - | - |
6 institutional shareholders have reduced their position in ACHL stock as of 30 Jun 24 compared to 8 in the previous quarter (a -25.00% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 26 | -16.13% | 22,188,649 | -5.62% | 55.08% | 1.61% | 8 | -55.56% | 6 | -25.00% |
| 31 Mar, 24 | 31 | 63.16% | 23,510,455 | 7.93% | 58.50% | 1.98% | 18 | 125.00% | 8 | 100.00% |
| 31 Dec, 23 | 19 | 11.76% | 21,782,170 | 10.61% | 54.36% | 2.23% | 8 | 33.33% | 4 | - |
| 30 Sep, 23 | 17 | 6.25% | 19,692,035 | -0.48% | 49.35% | 1.99% | 6 | 50.00% | 4 | -33.33% |
| 30 Jun, 23 | 16 | - | 19,786,405 | -2.22% | 49.80% | 1.92% | 4 | -33.33% | 6 | 200.00% |
| 31 Mar, 23 | 16 | -23.81% | 20,235,741 | -6.60% | 50.93% | 1.68% | 6 | -45.45% | 2 | -60.00% |
| 31 Dec, 22 | 21 | -19.23% | 21,665,748 | -20.55% | 55.11% | 1.15% | 11 | -15.38% | 5 | -16.67% |
| 30 Sep, 22 | 26 | 13.04% | 27,269,868 | 0.50% | 69.36% | 1.44% | 13 | 44.44% | 6 | - |
| 30 Jun, 22 | 23 | 4.55% | 27,135,177 | 2.13% | 69.39% | 1.49% | 9 | 12.50% | 6 | -14.29% |
| 31 Mar, 22 | 22 | -24.14% | 26,568,801 | -3.15% | 68.31% | 0.75% | 8 | -55.56% | 7 | 250.00% |
| 31 Dec, 21 | 29 | 45.00% | 27,433,848 | 55.90% | 95.74% | 4.53% | 18 | 200.00% | 2 | -50.00% |
| 30 Sep, 21 | 20 | -31.03% | 17,597,157 | -6.32% | 45.99% | 1.66% | 6 | -40.00% | 4 | -69.23% |
| 30 Jun, 21 | 29 | - | 18,784,796 | 11.77% | 52.64% | 2.37% | 10 | -65.52% | 13 | - |
| 31 Mar, 21 | 29 | - | 16,807,348 | - | 47.10% | - | 29 | - | - | - |
ACHL Ownership FAQ
Who Owns Achilles Therapeutics?
Achilles Therapeutics is owned by institutional shareholders (55.08%), insiders (6.51%), and public (38.40%). The largest institutional shareholder of Achilles Therapeutics is SYNCONA PORTFOLIO LTD (27.52% of total shares) and the top mutual fund owner is Collaborative Investment Series Trust (0.46% of total shares).
Who are the major institutional shareholders of Achilles Therapeutics?
Achilles Therapeutics's major institutional shareholders are SYNCONA PORTFOLIO LTD, FCPM III SERVICES B.V., REDMILE GROUP, LLC, VESTAL POINT CAPITAL, LP, and IKARIAN CAPITAL, LLC. The top five shareholders own together 44.76% of the company's share outstanding.
How many Achilles Therapeutics shareholders are there?
As of Jun 2024, there are 26 institutional shareholders of Achilles Therapeutics.
What percentage of Achilles Therapeutics is owned by SYNCONA PORTFOLIO LTD?
SYNCONA PORTFOLIO LTD owns 11.09M shares of Achilles Therapeutics, representing 27.52% of the company's total shares outstanding, valued at $9.04M (as of Jun 2024).
What percentage of Achilles Therapeutics is owned by FCPM III SERVICES B.V?
As of Jun 2024, FCPM III SERVICES B.V holds 2.39M shares of Achilles Therapeutics (ACHL), compromising 5.93% of the company, valued at $1.95M.
What percentage of Achilles Therapeutics is owned by REDMILE GROUP, LLC?
REDMILE GROUP, LLC is the third largest holder of Achilles Therapeutics. The company owns 1.61M of the company's shares outstanding (worth $1.31M).